WASHINGTON — The nation’s highest court has temporarily reinstated widespread availability of the abortion medication mifepristone on Monday, halting a decision that could have dramatically altered how abortions are accessed nationwide.
Justice Samuel Alito signed the temporary order that permits women to receive the medication from pharmacies or by mail delivery, eliminating the requirement for face-to-face medical consultations.
These accessibility guidelines had been operating for multiple years before a federal appeals court established additional limitations the previous week.
Most abortions performed in America involve medication protocols, typically combining mifepristone with another medication called misoprostol. The continued accessibility of these drugs has lessened the effects of abortion prohibitions that numerous Republican-controlled states have begun implementing following the Supreme Court’s 2022 decision that eliminated Roe v. Wade protections and permitted individual states to enact their own restrictions.
Louisiana brought legal action seeking to limit mifepristone access, claiming the drug’s availability weakened their state’s prohibition.
Several Democratic-controlled states have enacted legislation designed to provide legal safeguards for medical professionals who use telehealth services to prescribe these medications to patients residing in states with abortion bans.
Alito’s directive remains active for an additional seven days as both parties submit their responses and the court conducts a more comprehensive review of the matter.
The companies that produce mifepristone submitted urgent appeals requesting Supreme Court intervention.
